xii

Calpain Inhibitor XII (Z-L-Nva-CONH-CH2-2-Py) is a selective and potent inhibitor of calpain I, inhibits calpain II and cathepsin B. Calpain Inhibitor XII shows antiviral activity against coronavirus in cell culture.

Eupteleasaponin XII is a useful organic compound for research related to life sciences. The catalog number is T125110 and the CAS number is 290809-58-4.

RA-XII is a useful organic compound for research related to life sciences. The catalog number is T125868 and the CAS number is 143343-98-0.

hCAIX XII-IN-13 functions as an inhibitor targeting specific human carbonic anhydrases (hCA) IX and XII, crucial in tumor-related processes. Demonstrating efficacy, this compound offers inhibitory K i values of 0.08 µM for IX and 0.06 µM for XII. Additionally, under hypoxic conditions, hCAIX XII-IN-13 enhances the effectiveness of Doxorubicin on MCF-7 cells by promoting G2 M phase cell cycle arrest and increasing apoptosis.

hCAII XII-IN-1 (compound 4l) is a potent inhibitor of hCAXII and hCAII, with Ki values of 8.4 nM and 9.4 nM, respectively. It plays a significant role in cancer research.

hCAI II XII-IN-1 (compound 7) is an inhibitor of human carbonic anhydrases hCAI, hCAII, and hCAXII, with Ki values of 78.5 nM, 9.1 nM, 605 nM, 7.7 nM, and 3.7 nM.

hCAIX XII-IN-14 (Compound 1i) is an inhibitor of hCAIX and hCAXII, with Ki values of 9.4 nM for hCAII, 5.6 nM for hCAIX, and 6.3 nM for hCAXII.

hCAIX XII-IN-5 (Coumarin 9a) is an inhibitor of carbonic anhydrase (CA) with excellent selectivity for hCA IX XII, displaying Kis of 93.3 nM and 85.7 nM over hCA I and hCA II, respectively. It exhibits anti-proliferative activities in cancer cells, delaying the cell cycle and inducing apoptosis [1].

hCAIX XII-IN-2 (compound 6a) is a potent and selective inhibitor of hCAIX and hCAXII, with Ki values of >10000 nM for hCAI and hCAII, and 30.0 nM and 3.6 nM for hCAIX and hCAXII respectively [1].

hCAIX XII-IN-4 (compound 6c) is a highly potent inhibitor of CAIX XII, exhibiting Ki values of 4.5 nM for CAXII, 23.6 nM for CAIX, and >10000 nM for both CAI and CAⅡ, respectively [1].

hCAIX XII-IN-1, a potent inhibitor of both CAIX and CAXII, exhibits KI values of 0.48 μM for CAIX and 0.83 μM for CAXII, respectively. This compound demonstrates antiproliferative activity in vitro and induces apoptosis in MCF-7 cells [1].

hCAIX XII-IN-3 (compound 6q) is a potent, selective inhibitor of hCAIX and hCAXII, with K i values of >10000 nM for hCAI and hCAII, and 66.2 nM and 4.4 nM for hCAIX and hCAXII, respectively.

hA2A hCA XII modulator 1 is a potent antagonist of the hA2A adenosine receptor (hA2AAR), a triazolopyrazine that acts on hA2AAR (Ki: 6.4 nM), hA1AR (Ki: 4.819 μM), and hA3AR (Ki>30 μM). hA2A hCA XII modulator 1 Also a potent inhibitor of human carbonic anhydrase XII (hCA XII), capable of acting on hCA XII (Ki: 6.2 nM), hCA II (Ki: 46 nM), hCA IX (Ki: 466 nM) and hCA I (Ki: 8.351 μM). hA2A hCA XII modulator 1 exhibits potential for cancer research.

hCA XII II IX-IN-1 is a potent inhibitor of human carbonic anhydrase (hCA), acting on hCA I (IC50: 2.6 μM), hCA II (IC50: 0.004 μM), hCA IX (IC50: 0.005 μM), and hCA XII (IC50: 0.001 μM). hCA XII II IX-IN-1 exhibited anticancer effects.

hCAIX XII-IN-6, an orally active carbonic anhydrase (CA) inhibitor, targets human CA isoforms hCA I, II, IV, IX, and XII with inhibition constants (K i) of 6697 nM, 2950 nM, 4093 nM, 4.1 nM, and 7.7 nM, respectively. This compound is utilized in rheumatoid arthritis (RA) research.

Compound 4d, known as hCA XII-IN-6, is a potent inhibitor of human carbonic anhydrase XII (hCA XII) with a Ki value of 84.2 nM and exhibits anti-proliferative effects, making it useful in cancer research [1].

JH-XII-03-02 is a potent, selective leucine-rich repeat kinase 2 (LRRK2) proteolysis targeting chimera (PROTAC) degrader, utilized in Parkinson's Disease (PD) research [1].

Compound 3e (hCAIX XII-IN-7) is a potent inhibitor of human carbonic anhydrase (hCA) isozymes IX and XII, displaying inhibitory constants (Kis) of 503.7 nM for hCA IX and 59 nM for hCA XII, while also showing activity against hCA I and II with Kis of 3.2 nM and 9.2 nM, respectively. It holds potential for research into hypoxic tumors [1].

hCAIX XII-IN-8 (compound 3g) is a potent inhibitor of the human carbonic anhydrases (CAs) IX and XII, with inhibition constants (K i) of 8.5 nM for CA IX and 6.7 nM for CA XII. It demonstrates significant inhibitory efficacy particularly against tumor-associated, membrane-bound isoforms hCA IX and XII, while exhibiting high selectivity over the cytosolic isoforms hCA I and II [1].

Jingzhaotoxin-XII (JzTx-XII) functions as a potent inhibitor of the Kv4.1 channel, exhibiting an inhibitory concentration (IC50) of 0.363 μM. It modulates the channel's gating behavior [1].

Dipsacus saponin XII (compound 6) is a triterpenoid saponin that promotes proliferation and enhances alkaline phosphatase activity in UMR106 cells at a concentration of 4 μM.

Jingzhaotoxin-XII (JzTx-XII) TFA is a specific inhibitor of the Kv4.1 channel, exhibiting an IC50 of 0.363 μM. It interacts with the channel by altering gating behavior.

GSK-3 Inhibitor XIII, an ATP-competitive GSK-3 inhibitor (Ki: 24 nM), can be used to study diabetes and obesity.

CAIX CAXII-IN-4 (Compound 7h) is an inhibitor of carbonic anhydrase (CA) that binds to CAIX, CA XII, and CAII with Ki values of 1.324 μM, 0.435 μM, and 3.035 μM, respectively. This compound exhibits broad-spectrum anti-tumor activity and inhibits the proliferation of central nervous system tumor cells U251, with a GI50 of 0.361 μM.